Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País/Região como assunto
Intervalo de ano de publicação
1.
Genes Dev ; 33(3-4): 166-179, 2019 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-30692202

RESUMO

Although changes in alternative splicing have been observed in cancer, their functional contributions still remain largely unclear. Here we report that splice isoforms of the cancer stem cell (CSC) marker CD44 exhibit strikingly opposite functions in breast cancer. Bioinformatic annotation in patient breast cancer in The Cancer Genome Atlas (TCGA) database reveals that the CD44 standard splice isoform (CD44s) positively associates with the CSC gene signatures, whereas the CD44 variant splice isoforms (CD44v) exhibit an inverse association. We show that CD44s is the predominant isoform expressed in breast CSCs. Elimination of the CD44s isoform impairs CSC traits. Conversely, manipulating the splicing regulator ESRP1 to shift alternative splicing from CD44v to CD44s leads to an induction of CSC properties. We further demonstrate that CD44s activates the PDGFRß/Stat3 cascade to promote CSC traits. These results reveal CD44 isoform specificity in CSC and non-CSC states and suggest that alternative splicing provides functional gene versatility that is essential for distinct cancer cell states and thus cancer phenotypes.


Assuntos
Processamento Alternativo , Neoplasias da Mama/genética , Receptores de Hialuronatos/genética , Receptores de Hialuronatos/metabolismo , Células-Tronco Neoplásicas/patologia , Animais , Linhagem Celular Tumoral , Modelos Animais de Doenças , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Camundongos , Isoformas de Proteínas , Transdução de Sinais/genética
2.
Australas Phys Eng Sci Med ; 33(3): 285-97, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20882382

RESUMO

The results of a recent survey of Australian radiotherapy centres are presented. A total of 56 treatment centres were identified, operating 139 linacs, 26 kV units and 25 remote afterloaders. Of these centres, 51 participated in the survey (91%). Results are presented which summarize the beam qualities, dosimetry protocols, ion chambers and treatment modalities in clinical use. The results provide a snapshot of the equipment and practices used in radiotherapy in Australia in 2009.


Assuntos
Radiometria/métodos , Radioterapia/instrumentação , Austrália , Braquiterapia/instrumentação , Coleta de Dados , Elétrons/uso terapêutico , Humanos , Neoplasias/radioterapia , Aceleradores de Partículas/instrumentação , Fótons/uso terapêutico , Planejamento da Radioterapia Assistida por Computador
3.
J Clin Invest ; 121(3): 1064-74, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21393860

RESUMO

Epithelial-mesenchymal transition (EMT) is a tightly regulated process that is critical for embryogenesis but is abnormally activated during cancer metastasis and recurrence. Here we show that a switch in CD44 alternative splicing is required for EMT. Using both in vitro and in vivo systems, we have demonstrated a shift in CD44 expression from variant isoforms (CD44v) to the standard isoform (CD44s) during EMT. This isoform switch to CD44s was essential for cells to undergo EMT and was required for the formation of breast tumors that display EMT characteristics in mice. Mechanistically, the splicing factor epithelial splicing regulatory protein 1 (ESRP1) controlled the CD44 isoform switch and was critical for regulating the EMT phenotype. Additionally, the CD44s isoform activated Akt signaling, providing a mechanistic link to a key pathway that drives EMT. Finally, CD44s expression was upregulated in high-grade human breast tumors and was correlated with the level of the mesenchymal marker N-cadherin in these tumors. Together, our data suggest that regulation of CD44 alternative splicing causally contributes to EMT and breast cancer progression.


Assuntos
Processamento Alternativo , Neoplasias da Mama/patologia , Epitélio/metabolismo , Regulação Neoplásica da Expressão Gênica , Receptores de Hialuronatos/biossíntese , Receptores de Hialuronatos/genética , Mesoderma/metabolismo , Isoformas de Proteínas , Animais , Neoplasias da Mama/metabolismo , Caderinas/metabolismo , Linhagem Celular , Progressão da Doença , Transição Epitelial-Mesenquimal , Humanos , Neoplasias Mamárias Animais/metabolismo , Camundongos
4.
Cancer Res ; 69(20): 8183-90, 2009 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-19826042

RESUMO

Accumulating data have implicated the selenium-containing cytosolic glutathione peroxidase, GPx-1, as a determinant of cancer risk and a mediator of the chemopreventive properties of selenium. Genetic variants of GPx-1 have been shown to be associated with cancer risk for several types of malignancies. To investigate the relationship between GPx-1 enzyme activity and genotype, we measured GPx-1 enzyme activity and protein levels in human lymphocytes as a function of the presence of two common variations: a leucine/proline polymorphism at codon 198 and a variable number of alanine-repeat codons. Differences in GPx activity among these cell lines, as well as in the response to the low-level supplementation of the media with selenium, indicated that factors other than just genotype are significant in determining activity. To restrict the study to genotypic effects, human MCF-7 cells were engineered to exclusively express allelic variants representing a combination of either a codon 198 leucine or proline and either 5 or 7 alanine-repeat codons following transfection of GPx-1 expression constructs. Transfectants were selected and analyzed for GPx-1 enzyme activity and protein levels. GPx-1 with 5 alanines and a leucine at codon 198 showed a significantly higher induction when cells were incubated with selenium and showed a distinct pattern of thermal denaturation as compared with GPx-1 encoded by the other examined alleles. The collective data obtained using both lymphocytes and MCF-7 indicate that both intrinsic and extrinsic factors cooperate to ultimately determine the levels of this enzyme available to protect cells against DNA damage and mutagenesis.


Assuntos
Neoplasias da Mama/genética , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Glutationa Peroxidase/genética , Linfócitos/enzimologia , Polimorfismo Genético/genética , Selênio/farmacologia , Alanina/química , Alanina/genética , Alelos , Antioxidantes/farmacologia , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/enzimologia , Códon/genética , Dano ao DNA , Genótipo , Humanos , Leucina/química , Leucina/genética , Linfócitos/efeitos dos fármacos , Mutagênese , Prolina/química , Prolina/genética , Glutationa Peroxidase GPX1
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA